LOWER VACCINE DOSE ASSOCIATES WITH ANTI-CSP ANTIBODY DURABILITY AND FUNCTION: PHASE I TRIALS OF R21/MATRIX-M IN EUROPE AND AFRICA
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI